Sonova Holding (OTCMKTS:SONVY) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sonova Holding (OTCMKTS:SONVY) have been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, one has given a buy recommendation and two have given a strong buy recommendation to the company.

Several equities research analysts have issued reports on SONVY shares. BNP Paribas Exane raised shares of Sonova from a “strong sell” rating to a “strong-buy” rating in a report on Tuesday, March 10th. Zacks Research upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Jefferies Financial Group cut shares of Sonova from a “hold” rating to a “moderate sell” rating in a research note on Wednesday, March 18th.

Sonova Stock Down 0.4%

Shares of OTCMKTS SONVY opened at $43.25 on Friday. Sonova has a one year low of $42.26 and a one year high of $68.76. The business has a fifty day simple moving average of $51.11 and a 200 day simple moving average of $52.84. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.91 and a current ratio of 1.24.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.